In the past week, REVB stock has gone up by 8.45%, with a monthly decline of -66.41% and a quarterly plunge of -70.81%. The volatility ratio for the week is 7.47%, and the volatility levels for the last 30 days are 18.31% for Revelation Biosciences Inc The simple moving average for the past 20 days is -9.01% for REVB’s stock, with a -87.28% simple moving average for the past 200 days.
Is It Worth Investing in Revelation Biosciences Inc (NASDAQ: REVB) Right Now?
Moreover, the 36-month beta value for REVB is -0.08. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for REVB is 2.03M and currently, short sellers hold a 6.79% of that float. On June 25, 2025, REVB’s average trading volume was 1.01M shares.
REVB) stock’s latest price update
The stock price of Revelation Biosciences Inc (NASDAQ: REVB) has jumped by 530273 compared to previous close of 0.77. Despite this, the company has seen a gain of 8.45% in its stock price over the last five trading days. businesswire.com reported 2025-05-29 that SAN DIEGO–(BUSINESS WIRE)—- $REVB #AKI–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated.
REVB Trading at -59.96% from the 50-Day Moving Average
After a stumble in the market that brought REVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.57% of loss for the given period.
Stock Fundamentals for REVB
The total capital return value is set at -2.84. Equity return is now at value -233.26, with -154.33 for asset returns.
Currently, EBITDA for the company is -7.95 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To wrap up, the performance of Revelation Biosciences Inc (REVB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
